CT 52923Alternative Names: CT052923
Latest Information Update: 08 Jun 2006
At a glance
- Originator Kyowa Hakko; Millennium Pharmaceuticals
- Class Antineoplastics
- Mechanism of Action Platelet-derived growth factor receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer